Loading…
Loading…
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Shares of Crane (NYSE: CR - Get Free Report) have earned a consensus recommendation of "Buy" from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and two have given a strong buy recommendation to the company.
WALTHAM, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Crane NXT, Co. (NYSE: CXT), a global leader in authentication and traceability technologies, today announced its schedule for the company's second quarter 2026 results.
STAMFORD, Conn.--(BUSINESS WIRE)--Crane Company (NYSE: CR) announces the following schedule and teleconference information for its second quarter 2026 earnings release: Earnings Release: July 28, 2026 after close of market by public distribution and the Crane Company website at www.craneco.com. Teleconference: July 29, 2026 at 10:00 AM (Eastern) hosted by Alex Alcala, President & CEO, and Richard A. Maue, Executive Vice President & CFO. The call can be accessed in a listen-only mode via.
Vancouver, British Columbia – TheNewswire - June 29, 2026: Headwater Gold Inc. (CSE: HWG) (OTCQX: HWAUF) (the “Company” or “Headwater”) is pleased to announce that Centerra Gold Inc. (“Centerra”) (TSX: CG) has commenced drilling at Headwater's Crane Creek Project (“Crane Creek” or the “Project”) in western Idaho. The drill program is being operated and fully funded by Centerra pursuant to the earn-in agreement announced on December 3, 2025 . Highlights:
NEW YORK, June 18, 2026 /PRNewswire/ -- Brixmor Property Group Inc. (NYSE: BRX) ("Brixmor" or the "Company") announced today the release of its eighth annual Corporate Responsibility (CR) Report, which provides a comprehensive overview of the Company's CR strategy, initiatives, and 2025 performance. "This report highlights how central Corporate Responsibility is to how we operate and grow," stated Brian Finnegan, Chief Executive Officer and President.
enGene Therapeutics Inc. (Nasdaq: ENGN, âenGeneâ or the âCompanyâ), a clinical-stage, non-viral genetic medicines company today announced its financial
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for CR and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.